StemCells, Inc. (NASDAQ:STEM) announced today that President and Chief
Executive Officer Martin McGlynn will present an update on the Company
at the Jefferies & Company Third Annual Healthcare Conference to be held
June 17-18 in New York City. Mr. McGlynn is scheduled to speak at 3:45
p.m. Eastern Time on Thursday, June 18.
A live webcast of the presentation will be available at http://www.wsw.com/webcast/jeff35/stem/
as well as through the Company’s corporate website at http://www.stemcellsinc.com
under the Investors section. Interested parties are encouraged to
connect to the website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the webcast. A replay of the webcast will also
be accessible through the Company’s website for a period of 30 days
following the event.
About StemCells, Inc.
StemCells, Inc. is a clinical-stage biotechnology company focused on the
research, development and commercialization of products derived from
stem cell technologies. In its therapeutic product development programs,
StemCells is focused on developing cell-based therapeutics to treat
diseases of the central nervous system and liver. StemCells’ lead
product candidate, HuCNS-SC® cells, are highly purified human
neural stem cells which can be expanded and banked until they are
delivered as patient doses. StemCells has completed a Phase I clinical
trial of HuCNS-SC cells as a potential treatment for neuronal ceroid
lipofuscinosis (NCL), a rare and fatal neurodegenerative disease that
affects infants and young children. The trial data demonstrated that the
HuCNS-SC cells were well tolerated by the trial participants. StemCells
has also received approval from the U.S. Food and Drug Administration to
initiate a Phase I clinical trial of the HuCNS-SC cells as a potential
treatment for Pelizaeus-Merzbacher Disease (PMD), a rare and fatal brain
disorder that primarily affects young children. StemCells, through its
wholly owned subsidiaries Stem Cell Sciences UK Ltd and Stem Cell
Sciences Australia Pty, is also pursuing applications of its cell-based
technologies to develop research and drug screening tools, such as
cell-based assays, media and reagent tools, which the Company believes
represent nearer-term commercial opportunities. StemCells has exclusive
rights to approximately 55 issued or allowed U.S. patents and
approximately 200 granted or allowed non-U.S. patents. Further
information about StemCells is available on its web site at: www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning of the
U.S. securities laws, and is subject to the safe harbors created therein.
These statements include, but are not limited to, statements
regarding the positive results of the Company’s Phase I clinical trial,
including the safety and tolerability of its HuCNS-SC cells; the
prospects for the Company to pursue non-therapeutic applications of its
cell-based technologies; and the future business operations of the
Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur
after the date hereof. Such statements reflect management’s current
views and are based on certain assumptions that may or may not
ultimately prove valid. The Company’s actual results may vary materially
from those contemplated in such forward-looking statements due to risks
and uncertainties to which the Company is subject, including those
described under the heading “Risk Factors” in Item 1A of Part II of the
Company’s most recent Quarterly Report on Form 10-Q.
StemCells, Inc.
Megan Meloni, 650-475-3100 ext. 105
Investor
Relations
